Literature DB >> 26647717

Induction of partial immunity in both males and females is sufficient to protect females against sexual transmission of Chlamydia.

C P O'Meara1,2, C W Armitage1, A Kollipara1, D W Andrew1,3, L Trim1, M B Plenderleith4, K W Beagley1.   

Abstract

Sexually transmitted Chlamydia trachomatis causes infertility, and because almost 90% of infections are asymptomatic, a vaccine is required for its eradication. Mathematical modeling studies have indicated that a vaccine eliciting partial protection (non-sterilizing) may prevent Chlamydia infection transmission, if administered to both sexes before an infection. However, reducing chlamydial inoculum transmitted by males and increasing infection resistance in females through vaccination to elicit sterilizing immunity has yet to be investigated experimentally. Here we show that a partially protective vaccine (chlamydial major outer membrane protein (MOMP) and ISCOMATRIX (IMX) provided sterilizing immunity against sexual transmission between immunized mice. Immunizing male or female mice before an infection reduced chlamydial burden and disease development, but did not prevent infection. However, infection and inflammatory disease responsible for infertility were absent in 100% of immunized female mice challenged intravaginally with ejaculate collected from infected immunized males. In contrast to the sterilizing immunity generated following recovery from a previous chlamydial infection, protective immunity conferred by MOMP/IMX occurred independent of resident memory T cells. Our results demonstrate that vaccination of males or females can further protect the opposing sex, whereas vaccination of both sexes can synergize to elicit sterilizing immunity against Chlamydia sexual transmission.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26647717     DOI: 10.1038/mi.2015.125

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  29 in total

1.  Histopathologic changes related to fibrotic oviduct occlusion after genital tract infection of mice with Chlamydia muridarum.

Authors:  Anita A Shah; Justin H Schripsema; Mohammad T Imtiaz; Ira M Sigar; John Kasimos; Peter G Matos; Sandra Inouye; Kyle H Ramsey
Journal:  Sex Transm Dis       Date:  2005-01       Impact factor: 2.830

2.  Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein.

Authors:  Anja W Olsen; Frank Follmann; Karin Erneholm; Ida Rosenkrands; Peter Andersen
Journal:  J Infect Dis       Date:  2015-03-06       Impact factor: 5.226

Review 3.  ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases.

Authors:  Adriana Baz Morelli; Dorit Becher; Sandra Koernig; Anabel Silva; Debbie Drane; Eugene Maraskovsky
Journal:  J Med Microbiol       Date:  2012-03-22       Impact factor: 2.472

4.  The infecting dose of Chlamydia muridarum modulates the innate immune response and ascending infection.

Authors:  Heather K Maxion; Wei Liu; Mi-Hyang Chang; Kathleen A Kelly
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

Review 5.  Memory T cell subsets, migration patterns, and tissue residence.

Authors:  Scott N Mueller; Thomas Gebhardt; Francis R Carbone; William R Heath
Journal:  Annu Rev Immunol       Date:  2012-12-03       Impact factor: 28.527

6.  Effects of inoculating dose on the kinetics of Chlamydia muridarum genital infection in female mice.

Authors:  Alison J Carey; Kelly A Cunningham; Louise M Hafner; Peter Timms; Kenneth W Beagley
Journal:  Immunol Cell Biol       Date:  2009-02-10       Impact factor: 5.126

7.  A 5-year Chlamydia vaccination programme could reverse disease-related koala population decline: predictions from a mathematical model using field data.

Authors:  Andrew P Craig; Jon Hanger; Jo Loader; William A H Ellis; John Callaghan; Cathryn Dexter; Darryl Jones; Kenneth W Beagley; Peter Timms; David P Wilson
Journal:  Vaccine       Date:  2014-05-28       Impact factor: 3.641

8.  CD4+ T cell help guides formation of CD103+ lung-resident memory CD8+ T cells during influenza viral infection.

Authors:  Brian J Laidlaw; Nianzhi Zhang; Heather D Marshall; Mathew M Staron; Tianxia Guan; Yinghong Hu; Linda S Cauley; Joe Craft; Susan M Kaech
Journal:  Immunity       Date:  2014-10-09       Impact factor: 31.745

9.  Experimental genital infection of male guinea pigs with the agent of guinea pig inclusion conjunctivitis and transmission to females.

Authors:  D T Mount; P E Bigazzi; A L Barron
Journal:  Infect Immun       Date:  1973-12       Impact factor: 3.441

10.  Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma.

Authors:  M J Smyth; K Y Thia; S E Street; D MacGregor; D I Godfrey; J A Trapani
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

View more
  9 in total

Review 1.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

2.  Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs.

Authors:  Shradha Wali; Rishein Gupta; Jieh-Juen Yu; Gopala Krishna Koundinya Lanka; James P Chambers; M Neal Guentzel; Guangming Zhong; Ashlesh K Murthy; Bernard P Arulanandam
Journal:  Immunol Cell Biol       Date:  2016-12-19       Impact factor: 5.126

Review 3.  Zika Virus in the Male Reproductive Tract.

Authors:  Liesel Stassen; Charles W Armitage; David J van der Heide; Kenneth W Beagley; Francesca D Frentiu
Journal:  Viruses       Date:  2018-04-16       Impact factor: 5.048

4.  Primary ectocervical epithelial cells display lower permissivity to Chlamydia trachomatis than HeLa cells and a globally higher pro-inflammatory profile.

Authors:  Chongfa Tang; Chang Liu; Benoit Maffei; Béatrice Niragire; Henri Cohen; Aminata Kane; Anne-Claire Donnadieu; Yael Levy-Zauberman; Thomas Vernay; Juliette Hugueny; Etienne Vincens; Christine Louis-Sylvestre; Agathe Subtil; Yongzheng Wu
Journal:  Sci Rep       Date:  2021-03-12       Impact factor: 4.379

5.  A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars.

Authors:  Anja Weinreich Olsen; Ida Rosenkrands; Martin J Holland; Peter Andersen; Frank Follmann
Journal:  NPJ Vaccines       Date:  2021-04-19       Impact factor: 9.399

6.  Chlamydia trachomatis vaccines for genital infections: where are we and how far is there to go?

Authors:  Luis M de la Maza; Toni L Darville; Sukumar Pal
Journal:  Expert Rev Vaccines       Date:  2021-04-28       Impact factor: 5.217

7.  Immunization of a wild koala population with a recombinant Chlamydia pecorum Major Outer Membrane Protein (MOMP) or Polymorphic Membrane Protein (PMP) based vaccine: New insights into immune response, protection and clearance.

Authors:  Marion Desclozeaux; Amy Robbins; Martina Jelocnik; Shahneaz Ali Khan; Jon Hanger; Volker Gerdts; Andrew Potter; Adam Polkinghorne; Peter Timms
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

8.  A Systematic Review: The Role of Resident Memory T Cells in Infectious Diseases and Their Relevance for Vaccine Development.

Authors:  Visai Muruganandah; Harindra D Sathkumara; Severine Navarro; Andreas Kupz
Journal:  Front Immunol       Date:  2018-07-09       Impact factor: 7.561

9.  Detection of chlamydia infection within human testicular biopsies.

Authors:  Emily R Bryan; Robert I McLachlan; Luk Rombauts; Darren J Katz; Anusch Yazdani; Kristofor Bogoevski; Crystal Chang; Michelle L Giles; Alison J Carey; Charles W Armitage; Logan K Trim; Eileen A McLaughlin; Kenneth W Beagley
Journal:  Hum Reprod       Date:  2019-10-02       Impact factor: 6.918

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.